Nanocarrier-Based Delivery of SN22 as a Tocopheryl Oxamate Prodrug Achieves Rapid Tumor Regression and Extends Survival in High-Risk Neuroblastoma Models

Nanocarrier-Based Delivery of SN22 as a Tocopheryl Oxamate Prodrug Achieves Rapid Tumor Regression and Extends Survival in High-Risk Neuroblastoma Models

Despite the use of intensive multimodality therapy, the majority of high-risk neuroblastoma (NB) patients do not survive. Without significant improvements in delivery strategies, anticancer agents used as a first-line treatment for high-risk tumors often fail to provide clinically meaningful results...

Full description

Bibliographic Details
Main Authors: Ivan S. Alferiev, David T. Guerrero, Danielle Soberman, Peng Guan, Ferro Nguyen, Venkatadri Kolla, Ilia Fishbein, Blake B. Pressly, Garrett M. Brodeur, Michael Chorny
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:International Journal of Molecular Sciences
Subjects:
neuroblastoma
drug resistance
topoisomerase I inhibitor
SN22
high-risk disease
nanoparticle
Online Access:https://www.mdpi.com/1422-0067/23/3/1752

Internet

https://www.mdpi.com/1422-0067/23/3/1752

Similar Items